![](https://safeminds.org/wp-content/uploads/Arizona_254454838_1600-185x97.jpg)
Delays and Denials of Promised Services Common for People with Disabilities
Arizona Experiences a Breakdown of State Run Aid Arizona was once considered among the best places in the country for people with disabilities to reside. For decades, the state was a shining example to other states for implementing well run service programs for people with developmental disabilities. This was mainly due to an innovative and […]
![](https://safeminds.org/wp-content/uploads/stethoscope_138632673_1600-185x97.jpg)
Are the Newest AAP Autism Intervention Recommendations Too Rigid?
Changes in Treatment Evidence Make Some Doctors Question AAP’s Advice Earlier this year the American Academy of Pediatrics (AAP) updated their guidance on identifying, evaluating and supporting children with autism. The organization’s guidelines seem to lack specific recommendations regarding interventions and implied that more intensive services for young children can generally lead to greater improvements. […]
![](https://safeminds.org/wp-content/uploads/Insomnia-girl_35428904_1600-185x97.jpg)
Barriers and Facilitators to Treating Insomnia in Children with Autism, Other DDs
Parents and Professionals Report Significant Challenges Insomnia is highly prevalent in children with autism and other neurodevelopmental disorders (NDDs), yet little research exists on sleep treatment access, utilization, and provision in these groups. Canadian researchers conducted focus groups and interviews with parents and professionals regarding knowledge and interventions for sleep disorders among children with an […]
![](https://safeminds.org/wp-content/uploads/Experimental-laboratory_359522166_1600-185x97.jpg)
Two Study Participants Lost Ability to Walk During a Gene Therapy Clinical Trial
High Dosage of Experimental Drug Blamed for Temporary Outcome A clinical trial involving gene therapy for a condition linked to autism has been paused after two test subjects temporarily lost their ability to walk. The trial by the biopharmaceutical company Ultragenyx and biotech startup GeneTx focused on Angelman Syndrome, a rare genetic neurodevelopmental condition characterized […]
![](https://safeminds.org/wp-content/uploads/Prescription-drugs_123721416_1600-185x97.jpg)
Study Finds Bumetanide Ineffective at Controlling Most ASD Behaviors
However, Drug Exhibits Positive Results for Managing Repetitive Behaviors Bumetanide is a potent diuretic typically used to treat edema. Recent research shows that the drug has been associated with positive behavioral outcomes for children with autism spectrum disorder (ASD). However, a new study published in the Journal of the American Academy of Child & Adolescent […]
![](https://safeminds.org/wp-content/uploads/American-Flags_69873552_1600-185x97.jpg)
Special Needs Advocates Optimistic Over Biden Win
President Elect Intends to Execute a “Full Equality” Disability Plan While in Office Advocates for people with disabilities are feeling hopeful over former Vice President Joe Biden’s presidential win earlier this month. There is justification for this optimism. During a hard-fought campaign, Biden issued a comprehensive disability plan calling for “full equality” for individuals with […]